High productivity of human recombinant beta-interferon from a low-temperature perfusion culture

Journal of Biotechnology

Volumn 150, Issue 4, 2010, Pages 509-518

  Rodriguez, J ^a   Spearman, M ^a   Tharmalingam, T ^a   Sunley, K ^a   Lodewyks, C ^a   Huzel, N ^a   Butler, M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Aggregation; Batch; Bioreactor; Concentration; Denaturation; Hydrophobic; Interferon beta; Perfusion; Residence time; Temperature

Indexed keywords

AGGREGATION; BATCH; CONCENTRATION; HYDROPHOBIC; INTERFERON-BETA; PERFUSION; RESIDENCE TIME;

ANTIBIOTICS; BATCH CELL CULTURE; BIOREACTORS; ESCHERICHIA COLI; ESTERIFICATION; GENETIC ENGINEERING; GLYCOPROTEINS; GLYCOSYLATION; HYDROPHOBICITY; INTERFERONS; PRODUCTIVITY;

CELL CULTURE;

RECOMBINANT BETA INTERFERON;

ANIMAL CELL; ARTICLE; BATCH CELL CULTURE; CELL GROWTH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; CULTURE TECHNIQUE; DRUG DETERMINATION; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG STABILITY; DRUG STRUCTURE; FEMALE; GLYCOSYLATION; LOW TEMPERATURE; LOW TEMPERATURE PERFUSION CULTURE SYSTEM; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PRODUCTIVITY; SIALYLATION; TRANSITION TEMPERATURE; VOLUMETRY;

ANIMALS; BIOREACTORS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CHO CELLS; CRICETINAE; CRICETULUS; CULTURE MEDIA; HUMANS; INTERFERON-BETA; PROTEIN DENATURATION; RECOMBINANT PROTEINS; TEMPERATURE;

CRICETULUS GRISEUS; ESCHERICHIA COLI;

EID: 78649443723     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2010.09.959     Document Type: Article

References (68)

1. Abdullah M.A., Rahmah A.U., Sinskey A.J., Rha C.K. Cell engineering and molecular pharming for biopharmaceuticals. Open Med. Chem. J. 2008, 2:49-61.
2. Ahn W.S., Jeon J.J., Jeong Y.R., Lee S.J., Yoon S.K. Effect of culture temperature on erythropoietin production and glycosylation in a perfusion culture of recombinant CHO cells. Biotechnol. Bioeng. 2008, 101(6):1234-1244.
3. Al-Fageeh M.B., Marchant R.J., Carden M.J., Smales C.M. The cold-shock response in cultured mammalian cells: harnessing the response for the improvement of recombinant protein production. Biotechnol. Bioeng. 2006, 93(5):829-835.
4. Altamirano C., Paredes C., Illanes A., Cairo J.J., Godia F. Strategies for fed-batch cultivation of t-PA producing CHO cells: substitution of glucose and glutamine and rational design of culture medium. J. Biotechnol. 2004, 110(2):171-179.
5. Angepat S., Gorenflo V.M., Piret J.M. Accelerating perfusion process optimization by scanning non-steady-state responses. Biotechnol. Bioeng. 2005, 92(4):472-478.
6. Antonetti F., Finocchiaro O., Mascia M., Terlizzese M.G., Jaber A. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. 2002, 22(12):1181-1184.
7. Arnason B.G. Treatment of multiple sclerosis with interferon beta. Biomed. Pharmacother. 1999, 53(8):344-350.
8. Baik J.Y., Lee M.S., An S.R., Yoon S.K., Joo E.J., Kim Y.H., Park H.W., Lee G.M. Initial transcriptome and proteome analyses of low culture temperature-induced expression in CHO cells producing erythropoietin. Biotechnol. Bioeng. 2006, 93(2):361-371.
9. Bigge J.C., Patel T.P., Bruce J.A., Goulding P.N., Charles S.M., Parekh R.B. Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Anal. Biochem. 1995, 230(2):229-238.
10. Bollati-Fogolin M., Forno G., Nimtz M., Conradt H.S., Etcheverrigaray M., Kratje R. Temperature reduction in cultures of hGM-CSF-expressing CHO cells: effect on productivity and product quality. Biotechnol. Prog. 2005, 21(1):17-21.
11. Bumelis V, Bumeliene A., Gedminiene G., Smirnovas V., Sereikaite J., Maedelyte I. Investigation of thermal stability of recombinant human interferon-gamma. Biologija 2002, 2:37-41.
12. Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol. 2005, 68(3):283-291.
13. Butler M. Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by mammalian cell systems. Cytotechnology 2006, 50:57-76.
14. Chen Z.L., Wu B.C., Liu H., Liu X.M., Huang P.T. Temperature shift as a process optimization step for the production of pro-urokinase by a recombinant Chinese hamster ovary cell line in high-density perfusion culture. J. Biosci. Bioeng. 2004, 97(4):239-243.
15. Chofflon M., Ben-Amor A.F. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis. Clin. Neurol. Neurosurg. 2002, 104(3):244-248.
16. Chuppa S., Tsai Y.S., Yoon S., Shackleford S., Rozales C., Bhat R., Tsay G., Matanguihan C., Konstantinov K., Naveh D. Fermentor temperature as a tool for control of high-density perfusion cultures of mammalian cells. Biotechnol. Bioeng. 1997, 55(2):328-338.
17. Clark K.J., Chaplin F.W., Harcum S.W. Temperature effects on product-quality-related enzymes in batch CHO cell cultures producing recombinant tPA. Biotechnol. Prog. 2004, 20(6):1888-1892.
18. Conradt H.S., Egge H., Peter-Katalinic J., Reiser W., Siklosi T., Schaper K. Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. J. Biol. Chem. 1987, 262(30):14600-14605.
19. Derynck R., Remaut E., Saman E., Stanssens P., De Clercq E., Content J., Fiers W. Expression of human fibroblast interferon gene in Escherichia coli. Nature 1980, 287(5779):193-197.
20. Dissing-Olesen L., Thaysen-Andersen M., Meldgaard M., Hojrup P., Finsen B. The function of the human interferon-beta 1a glycan determined in vivo. J. Pharmacol. Exp. Ther. 2008, 326(1):338-347.
21. Durocher Y., Butler M. Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol. 2009, 20(6):700-707.
22. Ethier M., Saba J.A., Spearman M., Krokhin O., Butler M., Ens W., Standing K.G., Perreault H. Application of the StrOligo algorithm for the automated structure assignment of complex N-linked glycans from glycoproteins using tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17(24):2713-2720.
23. Familletti P.C., Rubinstein S., Pestka S. A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol. 1981, 78(Pt A):387-394.
24. Fernandez O., Mayorga C., Luque G., Guerrero M., Guerrero R., Leyva L., Leon A., Blanca M. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. J. Neurol. 2001, 248(5):383-388.
25. Filippini G., Munari L., Incorvaia B., Ebers G.C., Polman C., D'Amico R., Rice G.P. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003, 361(9357):545-552.
26. Fox S.R., Patel U.A., Yap M.G., Wang D.I. Maximizing interferon-gamma production by Chinese hamster ovary cells through temperature shift optimization: experimental and modeling. Biotechnol. Bioeng. 2004, 85(2):177-184.
27. Fox S.R., Yap M.X., Yap M.G., Wang D.I. Active hypothermic growth: a novel means for increasing total interferon-gamma production by Chinese-hamster ovary cells. Biotechnol. Appl. Biochem. 2005, 41(Pt 3):265-272.
28. Gorenflo V.M., Ritter J.B., Aeschliman D.S., Drouin H., Bowen B.D., Piret J.M. Characterization and optimization of acoustic filter performance by experimental design methodology. Biotechnol. Bioeng. 2005, 90(6):746-753.
29. Guile G.R., Rudd P.M., Wing D.R., Prime S.B., Dwek R.A. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal. Biochem. 1996, 240(2):210-226.
30. Gupta P., Hall C.K., Voegler A.C. Effect of denaturant and protein concentrations upon protein refolding and aggregation: a simple lattice model. Protein Sci. 1998, 7(12):2642-2652.
31. Han Y.K., Koo T.Y., Lee G.M. Enhanced interferon-beta production by CHO cells through elevated osmolality and reduced culture temperature. Biotechnol. Prog. 2009, 25(5):1440-1447.
32. Kagawa Y., Takasaki S., Utsumi J., Hosoi K., Shimizu H., Kochibe N., Kobata A. Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. J. Biol. Chem. 1988, 263(33):17508-17515.
33. Karpusas M., Nolte M., Benton C.B., Meier W., Lipscomb W.N., Goelz S. The crystal structure of human interferon beta at 2.2-A resolution. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(22):11813-11818.
34. Kasama K., Utsumi J., Matsuo-Ogawa E., Nagahata T., Kagawa Y., Yamazaki S., Satoh Y. Pharmacokinetics and biologic activities of human native and asialointerferon-beta s. J. Interferon Cytokine Res. 1995, 15(5):407-415.
35. Kazmierski M., Corredig M. Characterization of soluble aggregates from whey protein isolate. Food Hydrocolloids 2003, 17:685-692.
36. Konstantinov K., Goudar C., Ng M., Meneses R., Thrift J., Chuppa S., Matanguihan C., Michaels J., Naveh D. The " push-to-low" approach for optimization of high-density perfusion cultures of animal cells. Adv. Biochem. Eng. Biotechnol. 2006, 101:75-98.
37. Kuster B., Wheeler S.F., Hunter A.P., Dwek R.A., Harvey D.J. Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal. Biochem. 1997, 250(1):82-101.
38. Mager D.E., Neuteboom B., Efthymiopoulos C., Munafo A., Jusko W.J. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J. Pharmacol. Exp. Ther. 2003, 306(1):262-270.
39. Mahler H.C., Friess W., Grauschopf U., Kiese S. Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 2009, 98:2909-2934.
40. Mark D.F., Lu S.D., Creasey A.A., Yamamoto R., Lin L.S. Site-specific mutagenesis of the human fibroblast interferon gene. Proc. Natl. Acad. Sci. U. S. A. 1984, 81(18):5662-5666.
41. Meuwly F., Weber U., Ziegler T., Gervais A., Mastrangeli R., Crisci C., Rossi M., Bernard A., von Stockar U., Kadouri A. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality. J. Biotechnol. 2006, 123(1):106-116.
42. Morozova-Roche L., Malisauskas M. A false paradise-mixed blessings in the protein universe: the amyloid as a new challenge in drug development. Curr. Med. Chem. 2007, 14(11):1221-1230.
43. Morris A.M., Watzky M.A., Finke R.G. Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim. Biophys. Acta 2009, 1794(3):375-397.
44. Murdoch D., Lyseng-Williamson K.A. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis. BioDrugs 2005, 19(5):323-325.
45. Nam J.H., Zhang F., Ermonval M., Linhardt R.J., Sharfstein S.T. The effects of culture conditions on the glycosylation of secreted human placental alkaline phosphatase produced in Chinese hamster ovary cells. Biotechnol. Bioeng. 2008, 100(6):1178-1192.
46. Renard J.S.R., Macier C., Salles M., Madine E. Evidence that monoclonal antibody production kinetics is related to the integral of the viable cell curve in batch systems. Biotechnol. Lett. 1988, 10:91-96.
47. Roberts C.J., Darrington R.T., Whitley M.B. Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. J. Pharm. Sci. 2003, 92(5):1095-1111.
48. Rodriguez J., Spearman M., Huzel N., Butler M. Enhanced production of monomeric interferon-beta by CHO cells through the control of culture conditions. Biotechnol. Prog. 2005, 21(1):22-30.
49. Rubinstein S., Familletti P.C., Pestka S. Convenient assay for interferons. J. Virol. 1981, 37(2):755-758.
50. Runkel L., deDios C., Karpusas M., Betzenhauser M., Muldowney C., Zafari M., Benjamin C.D., Miller S., Hochman P.S., Whitty A. Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity. Biochemistry 2000, 39(10):2538-2551.
51. Runkel L., Meier W., Pepinsky R.B., Karpusas M., Whitty A., Kimball K., Brickelmaier M., Muldowney C., Jones W., Goelz S.E. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 1998, 15(4):641-649.
52. Sah H. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J. Control. Release 1999, 58:143-151.
53. Shahrokh Z., Stratton P.R., Eberlein G.A., Wang Y.J. Approaches to analysis of aggregates and demonstrating mass balance in pharmaceutical protein (basic fibroblast growth factor) formulations. J. Pharm. Sci. 1994, 83(12):1645-1650.
54. Sorensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., Jensen K., Kristensen O., Petersen T., Rasmussen S., Ravnborg M., et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003, 362(9391):1184-1191.
55. Spearman M., Rodriguez J., Huzel N., Butler M. Production and glycosylation of recombinant beta-interferon in suspension and cytopore microcarrier cultures of CHO cells. Biotechnol. Prog. 2005, 21(1):31-39.
56. Spearman M., Rodriguez J., Huzel N., Sunley K., Butler M. Effect of Culture Conditions on Glycosylation of Recombinant beta-Interferon in CHO Cells 2007, European Society for Animal Cell Technology, pp. 200-203.
57. Sunley K., Butler M. Strategies for the enhancement of recombinant protein production from mammalian cells by growth arrest. Biotechnol. Adv. 2010, 28(3):385-394.
58. Sunley K., Tharmalingam T., Butler M. CHO cells adapted to hypothermic growth produce high yields of recombinant beta-interferon. Biotechnol. Prog. 2008, 24(4):898-906.
59. Tharmalingam T., Sunley K., Butler M. High yields of monomeric recombinant beta-interferon from macroporous microcarrier cultures under hypothermic conditions. Biotechnol. Prog. 2008, 24(4):832-838.
60. Trummer E., Fauland K., Seidinger S., Schriebl K., Lattenmayer C., Kunert R., Vorauer-Uhl K., Weik R., Borth N., Katinger H., et al. Process parameter shifting. Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol. Bioeng. 2006, 94(6):1033-1044.
61. Tsuji K., Tsutani K. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations. Eur. J. Pharm. Biopharm. 2008, 68(3):496-502.
62. Vagenende V., Yap M., Trout B. Mechanisms of Protein Stabilization and Prevention of Protein Aggregation by Glycerol. Biochemistry 2009, 48(46):11084-11096.
63. Walsh G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 2006, 24(7):769-776.
64. Wang W. Instability, stabilization and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 1999, 185:129-188.
65. Wang W. Protein aggregation and its inhibition in biopharmaceuticals. Int. J. Pharm. 2005, 289:1-30.
66. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22(11):1393-1398.
67. Yoon S.K., Hwang S.O., Lee G.M. Enhancing effect of low culture temperature on specific antibody productivity of recombinant Chinese hamster ovary cells: clonal variation. Biotechnol. Prog. 2004, 20(6):1683-1688.
68. Yoon S.K., Song J.Y., Lee G.M. Effect of low culture temperature on specific productivity, transcription level, and heterogeneity of erythropoietin in Chinese hamster ovary cells. Biotechnol. Bioeng. 2003, 82(3):289-298.